Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Savara Inc.

In Hindsight, Savara Wishes It Led With Patient-Reported Secondary Endpoint For Molgradex

Orphan lung disease firm tries to sell Phase III setback in aPAP as a “successful failed study” but investors disagree, cutting Savara’s share price by three-quarters. Biotech hopes to talk with regulators after deeper dive into dataset.

Clinical Trials Drug Approval Standards

Merck Looks To Add Pneumonia To Zerbaxa Label; Market Value Not Clear

Merck unveiled Phase III data showing efficacy in hospital-acquired bacterial pneumonia, but branded drugs with this indication currently have not scored significant sales.

Clinical Trials Research & Development

Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year

Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.

Financing Business Strategies

Pipeline Watch: Phase III Starts With Oxabact, Imeglimin And Favipiravir

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Aravas Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Savara Inc.
  • Senior Management
  • Rob Neville, Chmn. & CEO
    Dave Lowrance, CFO
    Taneli Jouhikainen, MD, PhD, COO
    Peter Ginsberg, VP, Bus. Dev.
    Cecilia Ganslandt, MD, Head, Medical Affairs
  • Contact Info
  • Savara Inc.
    Phone: (512) 961-1891
    6836 Bee Cave Rd., Bldg. 3, Ste. 200
    Austin, TX 78746
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register